Difference between revisions of "Part:BBa K4601001"
Line 3: | Line 3: | ||
<partinfo>BBa_K4601001 short</partinfo> | <partinfo>BBa_K4601001 short</partinfo> | ||
− | + | This part is the 'E. coli' codon optimized version of ChrimsonR channelrhodopsin. | |
− | |||
===Usage and Biology=== | ===Usage and Biology=== | ||
+ | ChrimsonR is a channelrhodopsin derived from the CR Chrimson of 'Chlamydomonas noctigama' that is naturally red-shifted [1]. Compared to the Chrimson, ChrimsonR contains one point mutation K176R that does not modify the absorption properties, but increases the photocurrent generated upon light irradiation. ChrimsonR is a Na+ inward pump that is also capable of transporting H<sup>+</sup>, K<sup>+</sup> and Ca<sup>2+</sup>. It is one of the few microbial opsins in clinical trials for gene therapy for patients with documented diagnosis of non-syndromic Retinitis Pigmentosa [2]. | ||
+ | |||
+ | ===References=== | ||
+ | [1] Klapoetke NC, Murata Y, Kim SS, Pulver SR, Birdsey-Benson A, Cho YK, Morimoto TK, Chuong AS, Carpenter EJ, Tian Z, Wang J, Xie Y, Yan Z, Zhang Y, Chow BY, Surek B, Melkonian M, Jayaraman V, Constantine-Paton M, Wong GK-S, Boyden ES. Independent optical excitation of distinct neural populations. Nature Methods (2014) 11: 338–346. | ||
+ | |||
+ | [2] GenSight Biologics. A Phase 1/2a, Open-label, non-randomized, dose-eEscalation study to evaluate the safety and tolerability of GS030 in subjects with Retinitis Pigmentosa. clinicaltrials.gov (2022). | ||
<!-- --> | <!-- --> |
Revision as of 14:28, 11 October 2023
ChrimsonR
This part is the 'E. coli' codon optimized version of ChrimsonR channelrhodopsin.
Usage and Biology
ChrimsonR is a channelrhodopsin derived from the CR Chrimson of 'Chlamydomonas noctigama' that is naturally red-shifted [1]. Compared to the Chrimson, ChrimsonR contains one point mutation K176R that does not modify the absorption properties, but increases the photocurrent generated upon light irradiation. ChrimsonR is a Na+ inward pump that is also capable of transporting H+, K+ and Ca2+. It is one of the few microbial opsins in clinical trials for gene therapy for patients with documented diagnosis of non-syndromic Retinitis Pigmentosa [2].
References
[1] Klapoetke NC, Murata Y, Kim SS, Pulver SR, Birdsey-Benson A, Cho YK, Morimoto TK, Chuong AS, Carpenter EJ, Tian Z, Wang J, Xie Y, Yan Z, Zhang Y, Chow BY, Surek B, Melkonian M, Jayaraman V, Constantine-Paton M, Wong GK-S, Boyden ES. Independent optical excitation of distinct neural populations. Nature Methods (2014) 11: 338–346.
[2] GenSight Biologics. A Phase 1/2a, Open-label, non-randomized, dose-eEscalation study to evaluate the safety and tolerability of GS030 in subjects with Retinitis Pigmentosa. clinicaltrials.gov (2022).
Sequence and Features
- 10COMPATIBLE WITH RFC[10]
- 12COMPATIBLE WITH RFC[12]
- 21COMPATIBLE WITH RFC[21]
- 23COMPATIBLE WITH RFC[23]
- 25COMPATIBLE WITH RFC[25]
- 1000COMPATIBLE WITH RFC[1000]